A Revolution

in Inhaled


Developing treatments for smoking-related lung conditions

A Revolution

in Inhaled Therapeutics

Developing treatments for smoking-related lung conditions

Therapeutic Treatments for Lung Conditions

Pneuma is a med-tech and pharmaceutical company focused on the advancement of inhaled respiratory therapeutics. With a bold vision, advanced aerosol technology, and strategic partnerships, Pneuma brings new approaches and innovations to respiratory health that will significantly improve the existing standard-of-care and produce a positive impact on the health and well-being of the global community.

We focus our intellectual and financial capital on the illnesses and chronic health problems that come from smoking and smoking-related illnesses. Our treatments under development target smoking cessation, chronic obstructive pulmonary disease (COPD), non-small cell lung cancer (NSCLC), and reduced-risk nicotine (exclusively licensed to global consumer products company).

Consumer Reduced-Risk Nicotine

Smoking Cessation


Treatment of Lung Disorders

Non-Small cell Lung Cancer

Our Technology



The Pneuma team is composed of former executives from Merck, Bayer, and Boehringer Ingelheim. Our Medical Advisors are academic thought leaders in pulmonary medicine at leading medical research centers.



Founded in 2015, Pneuma Respiratory is a med-tech and pharmaceutical company with expertise in drug formulation development, aerosol physics and handheld digital device design. Pneuma is based in Boone, North Carolina, with operations in Shenzhen, China. Combining its proprietary aerosol generation technology with the precision of digital systems, Pneuma’s platform technology is driving multiple therapeutic and nontherapeutic programs. Pneuma has 34 issued patents and 104 pending applications covering its technology and products.


Please get

in touch

Fill out the form with any comments, questions, or to just say hello! Look out for an updated website experience coming soon.